Network analysis of eating disorder symptoms in women in perimenopause and early postmenopause
ggest that EDs and related symptoms may be more prevalent in midlife aged women during perimenopause compared with midlife aged women at pre-menopause. To date few studies have examined the...
Conclusion: Results corroborate previous studies and indicate that, similar to young adult samples, dissatisfaction with body image is a core feature of ED pathology across the lifespan.
Share
The Interplay Among Natural Menopause, Insomnia, and Cognitive Health: A Population-Based Study
Menopause is defined as the time of permanent cessation of ovarian function and transition from a reproductive to a non-reproductive phase of life. Menopausal transition is associated with changes in...
Conclusion: In a cohort of women who transitioned to menopause naturally, we found that earlier age at menopause is associated with a lower cognitive performance score. This association was further exacerbated and mediated, but not moderated by insomnia symptoms. Our findings support the potential mediating role of insomnia, as both a...
Share
Keep Moving to Retain the Healthy Self: The Influence of Physical Exercise in Health Anxiety among Chinese Menopausal Women
Source : https://www.mdpi.com/2076-328X/13/2/140
Menopause is a period of high incidence of chronic diseases. Women experience various physical and psychological discomforts during menopause, and hormonal changes exacerbate mood swings in menopausal women and also...
Conclusion: In response to the proposed research objectives, this study noted that approximately 45% of menopausal women experience different degrees of health anxiety. In addition, the results indicated that physical exercise, interpersonal competence, and emotional intelligence are important factors influencing health anxiety in menopausal...
Share
Conclusion: During the menopausal transition, approximately 50% to 75% of women have vasomotor symptoms and GSM symptoms. Hormonal therapy with estrogen is the first-line therapy for bothersome vasomotor symptoms and GSM symptoms, but nonhormonal medications (such as paroxetine and venlafaxine) also can be effective. Hormone therapy is not...
Share
Vasomotor Symptoms During Menopause: A Practical Guide on Current Treatments and Future Perspectives
VMS persist for a median duration of 7 years and have been associated with significant comorbidities such as cardiovascular disease, bone disease, and cognitive complaints. Women who experience VMS during...
Conclusion: While HT use is a consideration for a majority of symptomatic, healthy, and recently menopausal women, nonhormone options may be utilized for women with contraindications to HT use, or for those who prefer to avoid HT use for any reason. Emerging therapies may provide additional options for women with bothersome VMS.
Share